| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,620,000 |
| Market
Cap: |
10.32(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.1993 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Humanigen is a biopharmaceutical company focused on developing its immuno-oncology and immunology portfolio of monoclonal antibodies. Co. is focusing on the development of its key product candidate, lenzilumab, its Humaneered® anti-human GM-CSF immunotherapy, through a clinical research agreement to study the effect of lenzilumab on the safety of Yescarta®, axicabtagene ciloleucel including cytokine release syndrome, and neurotoxicity. Co. is creates combinatory gene-edited CAR-T therapies to improve efficacy. Co. is also developing its own chimeric antigen receptor T-cell programs based on the backbone of ifabotuzumab and HGEN005, in unmet medical need and rare/orphan oncology conditions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,042,996 |
| Total Buy Value |
$0 |
$0 |
$0 |
$2,263,990 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
386,350 |
386,350 |
| Total Sell Value |
$0 |
$0 |
$4,250 |
$4,250 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Moradi David |
Managing Member |
– – – |
2015-11-16 |
4/A |
B |
$1.26 |
$314,809 |
I/I |
243,063 |
311,000 |
0.01 |
- |
|
| Moradi David |
Managing Member |
– – – |
2015-11-16 |
4/A |
B |
$1.26 |
$314,809 |
D/D |
243,063 |
311,000 |
2.44 |
- |
|
| Moradi David |
|
– – – |
2015-11-16 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
67,937 |
|
- |
|
| Moradi David |
|
– – – |
2015-11-16 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
67,937 |
|
- |
|
| Shkreli Martin |
10% Owner |
– – • |
2015-11-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
414,085 |
|
- |
|
| Anthion Partners Ii Llc |
|
– – – |
2015-11-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
67,937 |
|
- |
|
| Anthion Partners Ii Llc |
|
– – – |
2015-11-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
67,937 |
|
- |
|
| Anthion Partners Ii Llc |
10% Owner |
– – • |
2015-11-16 |
4 |
B |
$1.26 |
$314,809 |
I/I |
243,063 |
311,000 |
1.5 |
- |
|
| Anthion Partners Ii Llc |
10% Owner |
– – • |
2015-11-16 |
4 |
B |
$1.26 |
$314,809 |
D/D |
243,063 |
311,000 |
2.45 |
- |
|
| Shkreli Martin |
10% Owner |
– – • |
2015-11-16 |
4 |
B |
$0.61 |
$444,198 |
D/D |
597,438 |
1,011,523 |
2.45 |
- |
|
160 Records found
|
|
Page 7 of 7 |
|
|
